Last reviewed · How we verify

Intravenous Clarithromycin — Competitive Intelligence Brief

Intravenous Clarithromycin (Intravenous Clarithromycin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Macrolide antibiotic. Area: Infectious Disease.

marketed Macrolide antibiotic Bacterial 50S ribosomal subunit Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Intravenous Clarithromycin (Intravenous Clarithromycin) — University of Athens. Clarithromycin is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Intravenous Clarithromycin TARGET Intravenous Clarithromycin University of Athens marketed Macrolide antibiotic Bacterial 50S ribosomal subunit
Azithromycin 1gm Azithromycin 1gm Ain Shams Maternity Hospital marketed Macrolide antibiotic Bacterial 50S ribosomal subunit
Clarithromycin (ST14) Clarithromycin (ST14) National Taiwan University Hospital marketed Macrolide antibiotic Bacterial 50S ribosomal subunit
AzaSite® AzaSite® Merck Sharp & Dohme LLC marketed Macrolide antibiotic Bacterial 50S ribosomal subunit
Azithromycin Ophthalmic Solution, 1% Azithromycin Ophthalmic Solution, 1% Merck Sharp & Dohme LLC marketed Macrolide antibiotic Bacterial 50S ribosomal subunit
Erythromycin, Azithromycin , Clarithromycin Erythromycin, Azithromycin , Clarithromycin Baqiyatallah Medical Sciences University marketed Macrolide antibiotic Bacterial 50S ribosomal subunit
Azithromycin or placebo tablets Azithromycin or placebo tablets Rigshospitalet, Denmark marketed Macrolide antibiotic Bacterial 50S ribosomal subunit

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Macrolide antibiotic class)

  1. Pfizer · 6 drugs in this class
  2. Grünenthal GmbH · 4 drugs in this class
  3. Merck Sharp & Dohme LLC · 3 drugs in this class
  4. University of Taubate · 2 drugs in this class
  5. Lihir Medical Centre · 2 drugs in this class
  6. Thomas Jefferson University · 2 drugs in this class
  7. Copenhagen Studies on Asthma in Childhood · 1 drug in this class
  8. Ain Shams Maternity Hospital · 1 drug in this class
  9. Celltrion · 1 drug in this class
  10. London School of Hygiene and Tropical Medicine · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Intravenous Clarithromycin — Competitive Intelligence Brief. https://druglandscape.com/ci/intravenous-clarithromycin. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing